Danaher

DHR

Market cap $140B

Mar Vista's U.S. Quality Premier strategy returned -10.17% net-of-fees in the first quarter of 2026, while the Russell 1000 and S&P 500 indices returned -4.18% and -4.33%, respectively. Johnson & Johnson appreciated 18.74% during the first quarter driven by strong Innovative Medicine growth and an improved outlook for the medical device segment. Taiwan Semiconductor Manufacturing reported a strong quarter and raised its outlook, as it continues to benefit from robust demand for leading-edge semiconductors.

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing  BREA, Calif., April 13, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are ad.

Danaher is an American healthcare company that manufactures and markets products used for advances in biotechnology, life sciences, and diagnostics. Danaher has increased its dividend for 13 consecutive years. And its dividend growth has been nothing short of spectacular. DHR has a strong financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.

WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

During the fourth quarter, we initiated a new position in the leading energy-focused specialty contracting company, Quanta Services. Within the existing portfolio, our biggest addition during the quarter was to MSCI, a leading provider of indexes and investment decision support tools. We also added to our position in Danaher Corporation.